User profiles for "author:Kartik Sehgal"

Kartik Sehgal

Dana-Farber Cancer Institute
Verified email at dfci.harvard.edu
Cited by 8792

[HTML][HTML] Post-acute COVID-19 syndrome

A Nalbandian, K Sehgal, A Gupta, MV Madhavan… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen
responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in …

[HTML][HTML] Extrapulmonary manifestations of COVID-19

A Gupta, MV Madhavan, K Sehgal, N Nair… - Nature medicine, 2020 - nature.com
Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …

[HTML][HTML] Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research

B Bikdeli, MV Madhavan, A Gupta… - Thrombosis and …, 2020 - thieme-connect.com
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …

Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy

K Sehgal, RR Gill, P Widick, P Bindal… - JAMA network …, 2021 - jamanetwork.com
Importance Despite approximately 40% of patients having Eastern Cooperative Oncology
Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark …

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

K Sehgal, R Das, L Zhang, R Verma… - Blood, The Journal …, 2015 - ashpublications.org
In preclinical studies, pomalidomide mediated both direct antitumor effects and immune
activation by binding cereblon. However, the impact of drug-induced immune activation and …

Targeting human dendritic cells in situ to improve vaccines

K Sehgal, KM Dhodapkar, MV Dhodapkar - Immunology letters, 2014 - Elsevier
Dendritic cells (DCs) provide a critical link between innate and adaptive immunity. The
potent antigen presenting properties of DCs makes them a valuable target for the delivery of …

[HTML][HTML] Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer

L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni… - Journal of Thoracic …, 2018 - Elsevier
Introduction Despite widespread administration of programmed death receptor 1 (PD-1)
pathway inhibitors among individuals with NSCLC, little is known about the safety and …

Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes

A Bikas, S Ahmadi, T Pappa, E Marqusee, K Wong… - Clinical Cancer …, 2023 - AACR
Purpose: RAS mutations occur across the spectrum of thyroid neoplasms, and more tools
are needed for better prognostication. The objective of this study was to evaluate how …

[HTML][HTML] Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

K Sehgal, A Portell, EV Ivanova… - The Journal of …, 2021 - Am Soc Clin Investig
Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells,
originally discovered through in vitro assays. Whether a similar phenomenon limits efficacy …

[HTML][HTML] Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

K Sehgal, R Patell, D Rangachari… - Translational cancer …, 2018 - ncbi.nlm.nih.gov
The discovery of molecular subtypes of non-small cell lung cancer (NSCLC) with oncogenic
driver mutations and translocations/rearrangements has led to successful development of …